New drug OBIZER monitored in rare bleeding disorder study
NCT ID NCT06461533
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This study tracks 25 people in Japan with acquired hemophilia A who receive the drug OBIZER to control bleeding. Researchers will watch for side effects and check if the drug helps stop bleeding episodes. The study does not change how doctors treat patients—it simply collects real-world data for up to 90 days after the last dose.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACQUIRED HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Takeda selected site
RECRUITINGTokyo, Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.